本帖最后由 老马 于 2012-1-13 21:20 编辑 . |; u' Q2 x# x, @& g, o
% o6 R9 x: Z5 M( U
爱必妥和阿瓦斯丁的比较
0 |- V. S/ ^4 ]" S. q; D6 s% q
: X" c$ o) O) N: n; N2 D9 N3 ihttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/7 i& d) w) q- i' F8 B
+ r6 o% H$ v: m3 l) e) _0 B
6 B# l+ ?4 p( T% b2 y6 Ahttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
, Q5 V) u$ \4 Z; s! I" V==================================================& u, H6 Y/ ~, Z" K
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)( d3 n. I) n# t* d/ U7 w# R
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.# I6 ]9 H# N; L) V2 b
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
r6 s5 [7 M; W) K1 t( m* H- z
|